Overview

A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Status:
Recruiting

Trial end date:
2023-05-31

Target enrollment:

Participant gender:

Summary

This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to other places in the body. Abexinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving abexinostat and pembrolizumab may work better in treating participants with solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Rahul Aggarwal

Collaborator:

Xynomic Pharmaceuticals, Inc.

Treatments:

Abexinostat
Pembrolizumab